Renovo Ltd. raised £21 million in a second round funding that should enable it to take two compounds, one for accelerating wound healing and one for preventing scarring, to the end of Phase II studies, and to put another four compounds into Phase I testing. (BioWorld International)
Oxford GlycoSciences plc said its lead product, Zavesca, a treatment for Gaucher's disease received marketing authorization from the European Commission and the company plans to launch the product on the European market in the spring. (Bioworld International)
Oxford GlycoSciences plc said its lead product, Zavesca, a treatment for Gaucher's disease received marketing authorization from the European Commission and the company plans to launch the product on the European market in the spring. (Bioworld International)
